1. Home
  2. STBA vs URGN Comparison

STBA vs URGN Comparison

Compare STBA & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo S&T Bancorp Inc.

STBA

S&T Bancorp Inc.

HOLD

Current Price

$44.22

Market Cap

1.6B

Sector

Finance

ML Signal

HOLD

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

HOLD

Current Price

$28.59

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STBA
URGN
Founded
1902
2004
Country
United States
United States
Employees
1209
291
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.4B
IPO Year
1995
2016

Fundamental Metrics

Financial Performance
Metric
STBA
URGN
Price
$44.22
$28.59
Analyst Decision
Hold
Strong Buy
Analyst Count
6
7
Target Price
$43.00
$29.29
AVG Volume (30 Days)
227.6K
955.5K
Earning Date
04-23-2026
05-06-2026
Dividend Yield
3.29%
N/A
EPS Growth
2.35
N/A
EPS
0.94
N/A
Revenue
N/A
$1,128,000.00
Revenue This Year
$10.20
$129.09
Revenue Next Year
$4.14
$70.96
P/E Ratio
$46.06
N/A
Revenue Growth
N/A
N/A
52 Week Low
$34.01
$3.42
52 Week High
$45.17
$32.37

Technical Indicators

Market Signals
Indicator
STBA
URGN
Relative Strength Index (RSI) 54.52 62.20
Support Level $42.25 $17.86
Resistance Level $44.89 $30.00
Average True Range (ATR) 0.80 1.90
MACD -0.13 0.19
Stochastic Oscillator 53.70 62.20

Price Performance

Historical Comparison
STBA
URGN

About STBA S&T Bancorp Inc.

S&T Bancorp Inc is a financial holding company providing a full range of financial services to individuals and businesses in Pennsylvania and Ohio, including retail and commercial banking products, cash management, and trust and brokerage services. Through its subsidiary, it offers consumer, commercial, and small business banking services, including time and demand deposits, commercial and consumer loans, brokerage and trust services, and manages private investment accounts for individuals and institutions. The company earns revenue mainly from interest on loans and securities and fees for financial services, with net interest income as the principal source of revenue, and incurs expenses for deposits, funding sources, provision for credit losses, and operating costs.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

Share on Social Networks: